
[â—€è¿”å›](./home.md)

# 3-MeO-PCP

<mark> è¿˜è¡Œ

![Ambulance2.png](/æ–‡ä»¶/Ambulance2.png)

**3-MeO-PCP ç›¸è¾ƒäºå…¶ä»–[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)ï¼Œå¯èƒ½æ›´å®¹æ˜“å¼•å‘[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)ã€[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—….md)ã€‚[\[1\]](#cite_note-3MeO3-1)[\[2\]](#cite_note-3MeO2-2)[\[3\]](#cite_note-3MeO1-3)**

å¼ºçƒˆä¸å»ºè®®é«˜å‰‚é‡æœç”¨æ­¤ç‰©è´¨ï¼Œæˆ–è¿ç»­å¤šæ—¥æœç”¨ï¼Œæˆ–ä¸å…¶ä»–å¢åŠ ç²¾ç¥ç—…é£é™©çš„ç‰©è´¨è”ç”¨ã€‚è¯¦æƒ…è¯·å‚é˜…[æ­¤ç« èŠ‚](#Toxicity_and_harm_potential)ã€‚

è¯·å‹¿ä¸ [4-MeO-PCP](/è¯ç‰©/4-MeO-PCP.md) æ··æ·†ã€‚

---

### 3-MeO-PCP æ‘˜è¦

| **åŸºæœ¬ä¿¡æ¯** | |
| --- | --- |
| **åŒ–å­¦ç»“æ„** | [![3-MeO-PCP.svg](/æ–‡ä»¶/3-MeO-PCP.svg)](/æ–‡ä»¶/3-MeO-PCP.svg) |
| **å¸¸ç”¨åç§°** | 3-MeO-PCP, 3-MeO |
| **å–ä»£åç§°** | 3-ç”²æ°§åŸºè‹¯ç¯å·±å“Œå•¶ (3-Methoxyphencyclidine) |
| **ç³»ç»Ÿå‘½å** | 1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine |
| **ç²¾ç¥æ´»æ€§åˆ†ç±»** | [è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md) |
| **åŒ–å­¦åˆ†ç±»** | [èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨.md) |

### âš ï¸ è­¦å‘Š
ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€æ–°é™ˆä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚

### å‰‚é‡ä¸æ—¶é•¿

| **[æŠ½å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | **å‰‚é‡** |
| --- | --- |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 2 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 5 - 10 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 10 - 20 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 20 - 25 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 25 mg + **ä¸¥é‡å‰‚é‡å¯èƒ½å¯¼è‡´ç²¾ç¥ç—…å’Œèºç‹‚ã€‚**[\[4\]](#cite_note-psychosis-4) |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 45 - 120 åˆ†é’Ÿ |

| **[å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | **å‰‚é‡** |
| --- | --- |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 2 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 4 - 8 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 8 - 15 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 15 - 25 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 25 mg + **ä¸¥é‡å‰‚é‡å¯èƒ½å¯¼è‡´ç²¾ç¥ç—…å’Œèºç‹‚ã€‚**[\[4\]](#cite_note-psychosis-4) |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 8 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 - 90 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 45 - 120 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2 - 3 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 1 - 2 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 48 å°æ—¶ |

| **[é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | **å‰‚é‡** |
| --- | --- |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 1 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 2 - 5 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 5 - 10 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 10 - 15 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 15 mg + **ä¸¥é‡å‰‚é‡å¯èƒ½å¯¼è‡´ç²¾ç¥ç—…å’Œèºç‹‚ã€‚**[\[4\]](#cite_note-psychosis-4) |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 3 - 5 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 5 - 30 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 45 - 90 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 1.5 - 2 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 45 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 48 å°æ—¶ |

> **[å…è´£å£°æ˜](/å…³äºæœ¬ç«™/å…è´£å£°æ˜.md)ï¼š** æœ¬ç«™çš„[å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md)ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[èµ„æº](/æ–‡æ¡£/ç½‘ç»œ.md)ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯å»ºè®®ï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚

| [ç›¸äº’ä½œç”¨](#Dangerous_interactions) | |
| --- | --- |
| [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) | ğŸ’” è”ç”¨å±é™© |

---

**3-ç”²æ°§åŸºè‹¯ç¯å·±å“Œå•¶**ï¼ˆä¹Ÿç§°ä¸º **3-MeO-PCP**ï¼‰æ˜¯ä¸€ç§è¾ƒå°‘ä¸ºäººçŸ¥çš„[èŠ³åŸºç¯å·±èƒºç±»](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨.md)æ–°å‹[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)ã€‚3-MeO-PCP æ˜¯[è‹¯ç¯å·±å“Œå•¶](/è¯ç‰©/PCP.md)ï¼ˆ**PCP**ï¼‰çš„è¡ç”Ÿç‰©ï¼Œåœ¨åŒ–å­¦ä¸Šä¸[ç”²æ°§oxetamine](/è¯ç‰©/MXE.md)å’Œ [3-MeO-PCE](/è¯ç‰©/3-MeO-PCE.md) ç­‰ç‰©è´¨ç›¸å…³ã€‚å®ƒé€šè¿‡é˜»æ–­å¤§è„‘ä¸­çš„ [NMDA å—ä½“](/æ–‡æ¡£/NMDAå—ä½“.md)äº§ç”Ÿä½œç”¨ã€‚

3-MeO-PCP æœ€åˆäº 1979 å¹´åœ¨å¯¹[è‹¯ç¯å·±å“Œå•¶](/è¯ç‰©/PCP.md)ï¼ˆPCPï¼‰è¡ç”Ÿç‰©çš„ç ”ç©¶ä¸­è¢«åˆæˆã€‚ç„¶è€Œï¼Œç›´åˆ° 1999 å¹´ï¼Œä¸€ä½åŒ–å John Q. Beagle çš„åŒ–å­¦å®¶æŠ¥å‘Šäº†å…¶ä¸ [PCP](/è¯ç‰©/PCP.md) çš„å®šæ€§ç›¸ä¼¼æ€§ä»¥åŠç›¸å½“çš„æ•ˆåŠ›ï¼Œå…¶åœ¨äººç±»èº«ä¸Šçš„æ´»æ€§æ‰è¢«æè¿°ã€‚[\[5\]](#cite_note-Morris2014-5) 2009 å¹´ï¼Œå®ƒå¼€å§‹åœ¨ bluelight.ru ç­‰åœ¨çº¿è®ºå›ä¸Šè¢«è®¨è®ºï¼Œå¹¶åœ¨[ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md)å¸‚åœºä¸Šå‡ºå”®ã€‚[\[5\]](#cite_note-Morris2014-5)

ä¸å…¶ä»–èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨ä¸€æ ·ï¼Œ3-MeO-PCP ä¼šå¼•èµ·ä¸€ç§è¢«ç§°ä¸ºâ€œ[è§£ç¦»æ€§éº»é†‰](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)â€çš„çŠ¶æ€ï¼Œå°½ç®¡æ®æŠ¥é“è¿™ç§ç¨‹åº¦å…·æœ‰é«˜åº¦çš„å‰‚é‡ä¾èµ–æ€§ä¸”æ•ˆæœå¤šå˜ã€‚å®ƒé€šå¸¸[å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)å’Œ[é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)ï¼Œè™½ç„¶ä¹Ÿå¯ä»¥[æŠ½å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)å’Œ[æ³¨å°„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)ã€‚äººä»¬æ³¨æ„åˆ°å®ƒçš„è¯æ•ˆä¸Šå‡è¿‡ç¨‹å¾®å¦™ï¼Œå¹¶ä¸”å€¾å‘äºäº§ç”Ÿ[æ¸…é†’é”™è§‰](/è¯æ•ˆ/å¦„æƒ³.md)ï¼Œè¿™å¯èƒ½å¯¼è‡´[å¼ºè¿«æ€§åŠ é‡](/è¯æ•ˆ/å¼ºè¿«æ€§åŠ é‡.md)ã€‚

å…³äº 3-MeO-PCP çš„è¯ç†å­¦ã€ä»£è°¢å’Œæ¯’æ€§çš„æ•°æ®éå¸¸å°‘ã€‚ç”±äºå…¶å¼ºæ•ˆçš„è‡´å¹»ä½œç”¨å’Œç¼ºä¹ç ”ç©¶ï¼Œå¼ºçƒˆå»ºè®®å¦‚æœä½¿ç”¨è¯¥ç‰©è´¨ï¼Œåº”é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/ä¼¤å®³å‡å°‘æªæ–½.md)ã€‚

## ç›®å½•

* [1 åŒ–å­¦](#Chemistry)
* [2 è¯ç†å­¦](#Pharmacology)
* [3 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [3.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [3.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        - [3.2.1 æ‰­æ›²](#Distortions)
        - [3.2.2 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
    + [3.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
        - [3.3.1 æŠ‘åˆ¶](#Suppressions)
    + [3.4 **å¬è§‰æ•ˆåº”**](#Auditory_effects)
    + [3.5 **åˆ†ç¦»æ•ˆåº”**](#Disconnective_effects)
    + [3.6 **è¶…ä¸ªäººæ•ˆåº”**](#Transpersonal_effects)
    + [3.7 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [4 æ¯’æ€§å’Œå±å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [4.1 ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›](#Dependence_and_abuse_potential)
    + [4.2 ç²¾ç¥ç—…](#Psychosis)
    + [4.3 æ³Œå°¿é“æ•ˆåº”](#Urinary_tract_effects)
    + [4.4 å±é™©çš„ç›¸äº’ä½œç”¨](#Dangerous_interactions)
* [5 æ³•å¾‹åœ°ä½](#Legal_status)
* [6 å¦è§](#See_also)
* [7 å¤–éƒ¨é“¾æ¥](#External_links)
    + [7.1 è®¨è®ºå’Œåª’ä½“](#Discussion_and_Media)
* [8 æ–‡çŒ®](#Literature)
* [9 å‚è€ƒæ–‡çŒ®](#References)

## åŒ–å­¦ {#Chemistry}

3-ç”²æ°§åŸºè‹¯ç¯å·±å“Œå•¶ï¼Œæˆ– 3-MeO-PCPï¼Œæ˜¯ä¸€ç§èŠ³åŸºç¯å·±èƒºç±»åˆæˆè§£ç¦»å‰‚ã€‚3-MeO-PCP åŒ…å«ä¸€ä¸ªç¯å·±çƒ·ï¼ˆä¸€ä¸ªå…­å…ƒé¥±å’Œç¯ï¼‰ï¼Œåœ¨ R1 ä½ç½®é”®åˆåˆ°å¦å¤–ä¸¤ä¸ªç¯ä¸Šã€‚å…¶ä¸­ä¸€ä¸ªç¯æ˜¯å“Œå•¶ç¯ï¼ˆä¸€ä¸ªå«æ°®å…­å…ƒç¯ï¼‰ï¼Œåœ¨å…¶æ°®åŸºå›¢å¤„é”®åˆã€‚å¦ä¸€ä¸ªç¯æ˜¯èŠ³é¦™è‹¯ç¯ï¼Œåœ¨ R3 ä½ç½®è¢«ç”²æ°§åŸºå–ä»£ã€‚

3-MeO-PCP æ˜¯ [PCP](/è¯ç‰©/PCP.md) çš„è¡ç”Ÿç‰©ï¼Œåœ¨ç»“æ„ä¸Šä¸ [4-MeO-PCP](/è¯ç‰©/4-MeO-PCP.md) ç±»ä¼¼ã€‚

## è¯ç†å­¦ {#Pharmacology}

æ›´å¤šä¿¡æ¯ï¼š[NMDA å—ä½“æ‹®æŠ—å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/NMDAå—ä½“æ‹®æŠ—å‰‚ç±»è¯ç‰©.md)

3-MeO-PCP å……å½“ [NMDA å—ä½“æ‹®æŠ—å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/NMDAå—ä½“æ‹®æŠ—å‰‚ç±»è¯ç‰©.md)ã€‚NMDAï¼ˆN-ç”²åŸº-D-å¤©å†¬æ°¨é…¸ï¼‰å—ä½“æ˜¯è°·æ°¨é…¸å—ä½“çš„ä¸€ç§ç‰¹å®šäºšå‹ï¼Œè°ƒèŠ‚å¤§è„‘å’Œè„Šé«“ç¥ç»å…ƒä¹‹é—´çš„ç”µä¿¡å·ä¼ é€’ï¼›ä¸ºäº†ä¼ é€’ä¿¡å·ï¼Œå—ä½“å¿…é¡»å¤„äºå¼€æ”¾çŠ¶æ€ã€‚

è§£ç¦»å‰‚é€šè¿‡ç»“åˆå¹¶é˜»æ–­ NMDA å—ä½“æ¥æŠ‘åˆ¶å…¶æ­£å¸¸åŠŸèƒ½ã€‚è¿™ç§å¯¹ç¥ç»ç½‘ç»œæ´»åŠ¨çš„ç ´åä¼šå¯¼è‡´æ­£å¸¸çš„è®¤çŸ¥å’Œæƒ…æ„Ÿå¤„ç†èƒ½åŠ›ä¸§å¤±ã€ç²¾ç¥è¿åŠ¨åŠŸèƒ½ä¸§å¤±ã€éº»é†‰ï¼Œæœ€ç»ˆå¯¼è‡´ç›¸å½“äºâ€œk-holeâ€çš„çŠ¶æ€ã€‚

3-MeO-PCP å¯¹ NMDA å—ä½“çš„ Ki å€¼ä¸º 20 nMï¼Œå¯¹ sigma-1 å—ä½“ä¸º 42 nMï¼Œå¯¹è¡€æ¸…ç´ è½¬è¿ä½“ (SERT) ä¸º 216 nMï¼Œå¯¹ H1 å—ä½“ä¸º 2960 nMã€‚[\[6\]](#cite_note-6) [\[7\]](#cite_note-.22AMCD.22-7) å®ƒä¸ NMDA å—ä½“çš„ç»“åˆäº²å’ŒåŠ›é«˜äº PCPï¼Œå¹¶ä¸”åœ¨ä¸‰ç§åŒåˆ†å¼‚æ„çš„èŒ´é¦™åŸºå–ä»£ç‰©ä¸­äº²å’ŒåŠ›æœ€é«˜ï¼Œå…¶æ¬¡æ˜¯ 2-MeO-PCP å’Œ 4-MeO-PCPã€‚[\[8\]](#cite_note-8) åƒå®ƒçš„å§Šå¦¹åŒ–åˆç‰© PCP ä¸€æ ·ï¼Œä¸æ°¯èƒºé…®ä¸åŒï¼Œ3-MeO-PCP æ˜¾ç¤ºå‡ºæŠ‘åˆ¶ç›¸å¯¹æœªè¢«ç ”ç©¶çš„ PCP2 è°·æ°¨é…¸å—ä½“çš„é«˜äº²å’ŒåŠ›ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]

å°½ç®¡æ›¾æœ‰äººå£°ç§° 3-MeO-PCP å…·æœ‰é˜¿ç‰‡ç±»æˆ–å¤šå·´èƒºèƒ½æ´»æ€§ï¼Œ[\[9\]](#cite_note-chemist-9) ä½†è¿™ä¸€å‡è®¾ä¸æ•°æ®ç›¸çŸ›ç›¾ï¼Œæ•°æ®æ˜¾ç¤º 3-MeO-PCP æ˜¯ NMDA å—ä½“çš„å¼ºæ•ˆé€‰æ‹©æ€§é…ä½“ï¼Œè€Œå¯¹ Âµ-é˜¿ç‰‡å—ä½“æˆ–å¤šå·´èƒºè½¬è¿ä½“æ²¡æœ‰æ˜æ˜¾çš„äº²å’ŒåŠ›ã€‚[\[10\]](#cite_note-AMCD2-10) 3-MeO-PCP ä¹‹å‰æ˜¯æ•ˆåŠ›è¾ƒä½çš„è§£ç¦»å‰‚ 4-MeO-PCPï¼Œå¹¶äº 2011 å¹´é¦–æ¬¡ä½œä¸º[ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md)ä¸Šå¸‚ã€‚[\[5\]](#cite_note-Morris2014-5)

## ä¸»è§‚æ•ˆåº” {#Subjective_effects}

3-MeO-PCP é€šå¸¸è¢«æè¿°ä¸ºæ¯”å…¶ä»–[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)å¦‚[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)æˆ– [MXE](/è¯ç‰©/MXE.md) æ›´å…·åˆºæ¿€æ€§ä¸”è‡´ç˜«æ€§æ›´å°ã€‚

åœ¨ä½å‰‚é‡ä¸‹ï¼Œå®ƒå¯ä»¥å¼•èµ·æ„Ÿå®˜å¢å¼ºï¼Œå¦‚[é¢œè‰²å¢å¼º](/è¯æ•ˆ/é¢œè‰²å¢å¼º.md)ã€[æ•é”åº¦å¢å¼º](/è¯æ•ˆ/è§†è§‰é”åº¦å¢å¼º.md)ã€[è§¦è§‰å¢å¼º](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md)ã€[å¬è§‰å¢å¼º](/è¯æ•ˆ/å¬è§‰å¢å¼º.md)å’Œ[èº¯ä½“æ§åˆ¶å¢å¼º](/è¯æ•ˆ/èº¯ä½“æ§åˆ¶å¢å¼º.md)ã€‚åœ¨ä¸­é«˜å‰‚é‡ä¸‹ï¼Œå®ƒè¡¨ç°å‡ºæ„Ÿå®˜æŠ‘åˆ¶ï¼Œå¦‚[è§¦è§‰æŠ‘åˆ¶](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md)ã€[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)ã€[å¬è§‰æŠ‘åˆ¶](/è¯æ•ˆ/å¬è§‰æŠ‘åˆ¶.md)å’Œ[æ•é”åº¦æŠ‘åˆ¶](/è¯æ•ˆ/è§†è§‰é”åº¦æŠ‘åˆ¶.md)ã€‚

åŸºäºå¤§é‡çš„ä½“éªŒæŠ¥å‘Šï¼Œä¼¼ä¹å®ƒæ¯”å…¶ä»–è§£ç¦»å‰‚æ›´æœ‰å¯èƒ½å¼•å‘[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)ã€[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—….md)ï¼ˆå¯èƒ½æ˜¯ç”±äºå…¶å¼‚å¸¸é«˜çš„æ•ˆåŠ›ã€[å¼ºè¿«æ€§](/è¯æ•ˆ/å¼ºè¿«æ€§åŠ é‡.md)å’Œä¸ç¨³å®šçš„å‰‚é‡ååº”ï¼‰ã€‚

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/æ–‡æ¡£/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md) è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…è¿™äº›å†…å®¹ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”å¹¶ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡é«˜å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¹¶ä¸”å¯èƒ½åŒ…æ‹¬ **æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”** ![Child.svg](/æ–‡ä»¶/Child.svg)

+ **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)** - ä¸å…¶ä»–è§£ç¦»å‰‚å¦‚[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)ã€[MXE](/è¯ç‰©/MXE.md) æˆ– [DCK](/è¯ç‰©/DCK.md) ç›¸æ¯”ï¼Œ3-MeO-PCP è¢«è®¤ä¸ºå…·æœ‰æ˜æ˜¾çš„åˆºæ¿€æ€§ã€‚è¿™ç§åˆºæ¿€è¢«æè¿°ä¸ºæ¸…æ™°è€Œå¾®å¦™ã€‚
+ **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/ä¸é€‚æ€§æ•´ä½“èº¯ä½“æ•ˆåº”.md)** - 3-MeO-PCP çš„èº¯ä½“å¿«æ„Ÿåœ¨å…¶é£æ ¼å˜åŒ–ä¸Šå¯æè¿°ä¸ºä¸€ç§é™æ­¢çš„ã€æŒç»­çš„ã€é”åˆ©çš„ã€åŒ…ç½—ä¸‡è±¡çš„ã€æ¬£å¿«çš„å…¨èº«ç¥ç»æœ«æ¢¢æ¿€æ´»ã€‚
+ **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)** - æ®æŠ¥é“ï¼Œä¸å¤§å¤šæ•°å…¶ä»–è§£ç¦»å‰‚ï¼ˆå¦‚[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)æˆ–[äºŒè‹¯å•¶](/è¯ç‰©/äºŒè‹¯å•¶.md)ï¼‰ç›¸æ¯”ï¼Œ3-MeO-PCP æ›´å®¹æ˜“å¼•èµ·æ¬£å¿«æ„Ÿï¼Œå°¤å…¶æ˜¯èºç‹‚å˜ä½“ã€‚
+ **[è§¦è§‰å¢å¼º](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md)** æˆ– **[è§¦è§‰æŠ‘åˆ¶](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md)** - åœ¨è¾ƒä½å‰‚é‡ä¸‹ï¼Œè¯¥åŒ–åˆç‰©å€¾å‘äºå¼•èµ·è§¦è§‰å¢å¼ºã€‚åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œè¿™ç§å¢å¼ºä¼šè½¬å˜ä¸ºè§¦è§‰æŠ‘åˆ¶å’Œ[éº»é†‰](/è¯æ•ˆ/é•‡ç—›.md)ã€‚
+ **[é•‡ç—›](/è¯æ•ˆ/é•‡ç—›.md)** - è¯¥ç‰©è´¨äº§ç”Ÿæ˜æ˜¾çš„æ‰‹æœ¯ç¯å¢ƒé€šå¸¸æ‰€éœ€çš„ç¥ç»ä¿¡å·é˜»æ–­éº»é†‰æ•ˆæœï¼Œä½†ä»…åœ¨è¾ƒå¼ºè‡³ä¸¥é‡å‰‚é‡èŒƒå›´å†…ã€‚
+ **[èº¯ä½“æ§åˆ¶å¢å¼º](/è¯æ•ˆ/èº¯ä½“æ§åˆ¶å¢å¼º.md)** æˆ– **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)** - åœ¨è¾ƒä½å‰‚é‡ä¸‹ï¼Œè¯¥åŒ–åˆç‰©é€šå¸¸ä¼šå¼•èµ·èº¯ä½“æ§åˆ¶çš„å¢å¼ºã€‚åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œè¿™ç§å¢å¼ºè½¬å˜ä¸ºè¿åŠ¨æ§åˆ¶ä¸§å¤±ã€‚
+ **[ç©ºé—´å®šå‘éšœç¢](/è¯æ•ˆ/å‘¨è¾¹ä¿¡æ¯è¯¯åˆ¤.md)** - ä¸æ°¯èƒºé…®ç­‰å…¶ä»–è§£ç¦»å‰‚ç›¸æ¯”ï¼Œè¿™ç§æ•ˆåº”ä»…åœ¨é«˜å‰‚é‡ä¸‹æ˜¾è‘—ã€‚
+ **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)** æˆ– **[é£Ÿæ¬²å¢å¼º](/è¯æ•ˆ/é£Ÿæ¬²å¢å¼º.md)** - 3-MeO-PCP çš„é£Ÿæ¬²æŠ‘åˆ¶å¯ä»¥è¯´ä¸å¦‚ [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md) å’Œ [æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md) ç­‰ç‰©è´¨é‚£æ ·å‰§çƒˆã€‚åƒæ°¯èƒºé…®ä¸€æ ·ï¼Œè¿™æ˜¯ç”±äºé«˜å‰‚é‡ä¸‹çš„ç”µä¿¡å·æ–­å¼€æ‰€è‡´ã€‚ä¸æ°¯èƒºé…®ä¸åŒçš„æ˜¯ï¼Œä¹Ÿå¯èƒ½ä½“éªŒåˆ°æ˜æ˜¾çš„é£Ÿæ¬²å¢å¼ºï¼Œä½†è¿™ä¸å¦‚å…¶å§Šå¦¹åŒ–åˆç‰© [PCP](/è¯ç‰©/PCP.md) æ˜¾è‘—ã€‚
+ **[æ¶å¿ƒæŠ‘åˆ¶](/è¯æ•ˆ/æ¶å¿ƒæŠ‘åˆ¶.md)**
+ **[ä¸å®è…¿](/è¯æ•ˆ/ä¸å®è…¿.md)**
+ **[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)** - è¿™ç§æ•ˆåº”å¯èƒ½å‡ºç°åœ¨ä¸¥é‡å‰‚é‡æ°´å¹³ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
+ **[èº¯ä½“è‡ªä¸»](/è¯æ•ˆ/èº¯ä½“è‡ªä¸».md)**
+ **[å—…è§‰å¹»è§‰](/è¯æ•ˆ/å—…è§‰å¹»è§‰.md)**
+ **[çœ¼çƒæ»‘åŠ¨](/è¯æ•ˆ/çœ¼çƒæ»‘åŠ¨.md)**
+ **[è§†ç‰©æŒ¯åŠ¨](/è¯æ•ˆ/è§†ç‰©æŒ¯åŠ¨.md)** - åœ¨é«˜å‰‚é‡ä¸‹ï¼Œäººçš„çœ¼çƒå¯èƒ½ä¼šå¼€å§‹è‡ªå‘åœ°å¿«é€Ÿæ¥å›æ‘†åŠ¨ï¼Œå¯¼è‡´è§†åŠ›å˜å¾—æ¨¡ç³Šå¹¶æš‚æ—¶å¤±ç„¦ã€‚[\[11\]](#cite_note-Berar_et._al-11) è¿™æ˜¯ä¸€ç§è¢«ç§°ä¸º[çœ¼çƒéœ‡é¢¤](http://en.wikipedia.org/wiki/Nystagmus)çš„ç—…ç—‡ã€‚
+ **[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md)**
+ **[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md)** - è¿™ç§æ•ˆåº”éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—æ›´åŠ æ˜æ˜¾ã€‚[\[11\]](#cite_note-Berar_et._al-11)
+ **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**[\[11\]](#cite_note-Berar_et._al-11) - æ®æŠ¥é“ï¼Œè¿™ç§æ•ˆåº”æ¯”å…¶ä»–è§£ç¦»å‰‚å¦‚ [DCK](/è¯ç‰©/DCK.md) æˆ– [äºŒè‹¯å•¶](/è¯ç‰©/äºŒè‹¯å•¶.md) æ›´ä¸ºæ˜æ˜¾ã€‚
+ **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md)**
+ **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md)**
+ **[å¤´æ™•](/è¯æ•ˆ/å¤´æ™•.md)**
+ **[æ’å°¿å›°éš¾](/è¯æ•ˆ/æ’å°¿å›°éš¾.md)**
+ **[ç™«ç—«å‘ä½œ](/è¯æ•ˆ/ç™«ç—«å‘ä½œ.md)** - è¿™ç§æ•ˆåº”çš„å‘ç”Ÿç¨‹åº¦å°šä¸æ¸…æ¥šï¼Œä½†å¾ˆå¯èƒ½å‘ç”Ÿåœ¨æœ‰æ˜“æ„Ÿä½“è´¨çš„äººèº«ä¸Šï¼Œå°¤å…¶æ˜¯åœ¨èº«ä½“è´Ÿæ‹…é‡çš„æƒ…å†µä¸‹ï¼Œå¦‚è„±æ°´ã€ç–²åŠ³æˆ–è¥å…»ä¸è‰¯ã€‚

### **è§†è§‰æ•ˆåº”** ![Eye.svg](/æ–‡ä»¶/Eye.svg)

+ **[è§†è§‰é”åº¦å¢å¼º](/è¯æ•ˆ/è§†è§‰é”åº¦å¢å¼º.md)** æˆ– **[è§†è§‰é”åº¦æŠ‘åˆ¶](/è¯æ•ˆ/è§†è§‰é”åº¦æŠ‘åˆ¶.md)** - è™½ç„¶è¯¥åŒ–åˆç‰©çš„è¾ƒä½å‰‚é‡å€¾å‘äºäº§ç”Ÿè½»å¾®çš„è§†è§‰é”åº¦å¢å¼ºï¼Œä½†éšç€å‰‚é‡å¢åŠ ï¼Œè¿™ç§æ•ˆåº”å¾ˆå¿«æ¶ˆå¤±ï¼Œä¸€èˆ¬è§†è§‰åŠŸèƒ½å—åˆ°æŠ‘åˆ¶ã€‚
+ **[å¤è§†](/è¯æ•ˆ/å¤è§†.md)**
+ **[å¸§ç‡æŠ‘åˆ¶](/è¯æ•ˆ/è§†è§‰åŠ å·¥å‡æ…¢.md)**
+ **[æ¨¡å¼è¯†åˆ«æŠ‘åˆ¶](/è¯æ•ˆ/æ¨¡å¼è¯†åˆ«æŠ‘åˆ¶.md)**
#### æ‰­æ›²
+ **[é€è§†æ‰­æ›²](/è¯æ•ˆ/è§†è§‰æ‰­æ›².md)**
+ **[æ™¯è‰²åˆ‡å‰²](/è¯æ•ˆ/è§†è§‰æ‰­æ›².md)**
#### å¹»è§‰çŠ¶æ€
+ **[å†…éƒ¨å¹»è§‰](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)** (*[è®¾ç½®ã€æ™¯è‰²å’Œæ™¯è§‚](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)*; *[é€è§†å¹»è§‰](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)* å’Œ *[åœºæ™¯å’Œæƒ…èŠ‚](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)*)

### **è®¤çŸ¥æ•ˆåº”** ![User.svg](/æ–‡ä»¶/User.svg)

+ **[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/ç„¦è™‘æŠ‘åˆ¶.md)**
+ **[å»æŠ‘åˆ¶](/è¯æ•ˆ/å»æŠ‘åˆ¶.md)**
+ **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ¬£å¿«æ„Ÿ.md)**
+ **[å¼ºè¿«æ€§åŠ é‡](/è¯æ•ˆ/å¼ºè¿«æ€§åŠ é‡.md)** - è¿™ç§æ•ˆåº”æ ¹æ®ç»™è¯é€”å¾„çš„ä¸åŒè€Œæ›´åŠ æ˜¾è‘—ã€‚ä¾‹å¦‚ï¼Œå½“æŠ½å¸æˆ–é›¾åŒ–æ—¶ï¼Œç”±äºç‰©è´¨è¿›å…¥å’Œç¦»å¼€è¡€æ¶²ç›¸å¯¹çªç„¶ï¼Œè¿™ä¸€ç‚¹å°¤ä¸ºæ˜æ˜¾ã€‚
+ **[æ¦‚å¿µæ€§æ€ç»´](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[åˆ›é€ åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[æ—¢è§†æ„Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)** - æ®æŠ¥é“ï¼Œè¿™ç§æ•ˆåº”åœ¨ 3-MeO-PCP ä¸Šæ¯”å¤§å¤šæ•°å…¶ä»–è§£ç¦»å‰‚æ›´å¸¸è§ã€‚å®ƒé€šå¸¸å‘ç”Ÿåœ¨ä½“éªŒçš„è¯æ•ˆè¤ªå»æœŸï¼Œä½†ä¹Ÿå¯èƒ½å‘ç”Ÿåœ¨è¯æ•ˆå‘ä½œå’Œè¯æ•ˆä¸Šå‡æœŸã€‚
+ **[äººæ ¼è§£ä½“](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)** & **[ç°å®è§£ä½“](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)**
+ **[ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—….md)** - æ®æŠ¥é“ï¼Œè¿™ç§æ•ˆåº”åœ¨ 3-MeO-PCP ä¸Šæ¯”å¤§å¤šæ•°å…¶ä»–è§£ç¦»å‰‚ï¼ˆå¦‚ [MXE](/è¯ç‰©/MXE.md) æˆ– [æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)ï¼‰æ›´å¸¸è§ã€‚å®ƒé€šå¸¸å‘ç”Ÿåœ¨ä½“éªŒçš„[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)æœŸï¼Œä½†ä¹Ÿå¯èƒ½å‘ç”Ÿåœ¨[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)å’Œè¯æ•ˆä¸Šå‡æœŸã€‚
+ **[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)** - åƒç²¾ç¥ç—…ä¸€æ ·ï¼Œè¿™ç§æ•ˆåº”æ®æŠ¥é“åœ¨ 3-MeO-PCP ä¸Šæ¯”å¤§å¤šæ•°å…¶ä»–è§£ç¦»å‰‚æ›´å¸¸è§ã€‚
+ **[æ¢¦å¢ƒå¢å¼º](/è¯æ•ˆ/ä¿ƒæ¢¦å‰‚.md)**
+ **[è®°å¿†æŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
    - **[è‡ªæˆ‘æ­»äº¡](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)**
    - **[å¥å¿˜](/è¯æ•ˆ/å¥å¿˜.md)**
+ **[æ²‰æµ¸æ„Ÿå¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[éŸ³ä¹æ¬£èµå¢å¼º](/è¯æ•ˆ/å¬è§‰å¢å¼º.md)**
+ **[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
+ **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)** - æ®æŠ¥é“è¿™å­˜åœ¨äºè¾ƒä½å‰‚é‡èŒƒå›´å†…ã€‚
#### æŠ‘åˆ¶
[æˆç˜¾æŠ‘åˆ¶](/è¯æ•ˆ/æˆç˜¾æŠ‘åˆ¶.md)

### **å¬è§‰æ•ˆåº”** ![Volume-up.svg](/æ–‡ä»¶/Volume-up.svg)

+ **[å¬è§‰å¢å¼º](/è¯æ•ˆ/å¬è§‰å¢å¼º.md)** - æ®æŠ¥é“è¿™ç§æ•ˆåº”ä»…åœ¨ä½å‰‚é‡ä¸‹å‘ç”Ÿã€‚
+ **[å¬è§‰æŠ‘åˆ¶](/è¯æ•ˆ/å¬è§‰æŠ‘åˆ¶.md)**
+ **[å¬è§‰æ‰­æ›²](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md)**
+ **[å¬è§‰å¹»è§‰](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md)**

### **[åˆ†ç¦»æ•ˆåº”](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)** ![Chain-broken.svg](/æ–‡ä»¶/Chain-broken.svg)

+ **[è§¦è§‰åˆ†ç¦»](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)**
+ **[è§†è§‰åˆ†ç¦»](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)** - è¿™æœ€ç»ˆå¯¼è‡´ 3-MeO-PCP ç›¸å½“äºâ€œ[k-hole](https://en.wikipedia.org/wiki/K-hole)â€çš„çŠ¶æ€ï¼Œæˆ–æ›´å…·ä½“åœ°è¯´ï¼Œæ˜¯*[ç©ºæ´ã€ç©ºé—´å’Œè™šæ— ](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)*ä»¥åŠ*[ç»“æ„](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)*ã€‚
+ **[æ„è¯†åˆ†ç¦»](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)**

### **[è¶…ä¸ªäºº](/è¯æ•ˆ/ç²¾ç¥æ¢ç´¢.md)æ•ˆåº”** ![Infinity4.svg](/æ–‡ä»¶/Infinity4.svg)

+ **[å­˜åœ¨ä¸»ä¹‰è‡ªæˆ‘å®ç°](/è¯æ•ˆ/ç²¾ç¥æ¢ç´¢.md)**

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©åœ¨æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](/æŠ¥å‘Š/psychounautwiki/Experience_index)ä¸­çš„æ•ˆæœçš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

* [ä½“éªŒ:17mg 3-MeO-PCP & å¤§éº»æ²¹ - å¯æ€•çš„å›°æƒ‘](/æŠ¥å‘Š/psychounautwiki/Experience:17mg_3-MeO-PCP_%26_Cannabis_oil_-_Terrifying_confusion)
* [ä½“éªŒ:25mg 3-MeO-PCP - å¢å¼ºçš„ç”µå½±ä½“éªŒ](/æŠ¥å‘Š/psychounautwiki/Experience:25mg_3-MeO-PCP_-_Enhanced_film_experience)
* [ä½“éªŒ:3-MeO-PCP - æåº¦ç²¾ç¥ç—…](/æŠ¥å‘Š/psychounautwiki/Experience:3-MeO-PCP_-_Extreme_psychosis)
* [ä½“éªŒ:3-MeO-PCP 14mg å£æœ - ä¸€ä¸ªå¯’å†·æ„‰å¿«çš„å¤œæ™š](/æŠ¥å‘Š/psychounautwiki/Experience:3-MeO-PCP_14mg_Oral_-_A_chill_enjoyable_evening)
* [ä½“éªŒ:3-MeO-PCP, LSD, æ°¯ç¡å”‘ä»‘, å’Œè‹¯ä¸™èƒº - è¿‡é‡å’Œè¿‡åº¦çš„å›°æƒ‘](/æŠ¥å‘Š/psychounautwiki/Experience:3-MeO-PCP,_LSD,_Clonazolam,_and_Amphetamine_-_Excessive_Amounts_and_Excessive_Confusion)


æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: 3-MeO-PCP](https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml)


## æ¯’æ€§å’Œå±å®³æ½œåŠ› {#Toxicity_and_harm_potential}

æ›´å¤šä¿¡æ¯ï¼š[ç ”ç©¶ç”¨åŒ–å­¦å“ Â§ æ¯’æ€§å’Œå±å®³æ½œåŠ›](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md#æ¯’æ€§å’Œå±å®³æ½œåŠ›)ï¼Œå’Œ [è´Ÿè´£ä»»çš„ç”¨è¯ Â§ è‡´å¹»å‰‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md#è‡´å¹»å‰‚)

3-MeO-PCP å¨±ä¹æ€§ä½¿ç”¨çš„æ¯’æ€§å’Œé•¿æœŸå¥åº·å½±å“å°šæœªåœ¨ä»»ä½•ç§‘å­¦èƒŒæ™¯ä¸‹è¿›è¡Œç ”ç©¶ï¼Œç¡®åˆ‡çš„æœ‰æ¯’å‰‚é‡å°šä¸æ¸…æ¥šã€‚è¿™æ˜¯å› ä¸º 3-MeO-PCP çš„äººç±»ä½¿ç”¨å†å²éå¸¸çŸ­ã€‚

åŒ»å­¦æ–‡çŒ®ä¸­è®°å½•äº†ä¸€ä¾‹æ¶‰åŠè¯¥ç‰©è´¨çš„æ­»äº¡æ¡ˆä¾‹ã€‚åœ¨è¿™ç§æƒ…å†µä¸‹ï¼Œä¸ªäººçš„æ­»å› è¢«ç¡®å®šä¸º 3-MeO-PCPã€[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md)å’Œ[è‹¯æµ·æ‹‰æ˜](/è¯ç‰©/è‹¯æµ·æ‹‰æ˜.md)çš„æ··åˆä½¿ç”¨ã€‚[\[12\]](#cite_note-12)

### ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›

é•¿æœŸä½¿ç”¨ 3-MeO-PCP ä¼šäº§ç”Ÿä¾èµ–æ€§ï¼Œå¹¶ä¸”å…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ã€‚ä¸å…¶ä»–[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)ç›¸æ¯”ï¼Œæ®æŠ¥é“ 3-MeO-PCP æ¯”å…¶ä»–è§£ç¦»å‰‚æ›´å®¹æ˜“äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚ä¸€æ—¦å½¢æˆä¾èµ–ï¼Œå¦‚æœçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ[æˆ’æ–­ååº”](/æ–‡æ¡£/è¯ç‰©æˆ’æ–­ååº”.md)ã€‚ç½‘ä¸Šæœ‰å¤šä»½æŠ¥å‘Šç§°ç”¨æˆ·å¯¹è¯¥ç‰©è´¨äº§ç”Ÿäº†ä¸¥é‡çš„ä¾èµ–ã€‚

éšç€é•¿æœŸå’Œé‡å¤ä½¿ç”¨ï¼Œä¼šå¯¹ 3-MeO-PCP çš„è®¸å¤šæ•ˆæœäº§ç”Ÿè€å—æ€§ã€‚è¿™å¯¼è‡´ç”¨æˆ·å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚ä¹‹åï¼Œè€å—æ€§å‡å°‘åˆ°ä¸€åŠå¤§çº¦éœ€è¦ 3 - 7 å¤©ï¼Œæ¢å¤åˆ°åŸºçº¿éœ€è¦ 1 - 2 å‘¨ï¼ˆåœ¨ä¸å†æ‘„å…¥çš„æƒ…å†µä¸‹ï¼‰ã€‚3-MeO-PCP ä¸æ‰€æœ‰[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æœç”¨ 3-MeO-PCP åï¼Œæ‰€æœ‰[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)çš„æ•ˆæœéƒ½ä¼šé™ä½ã€‚

### ç²¾ç¥ç—…

æ®æŠ¥é“ï¼Œ3-MeO-PCP å¼•å‘[ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—….md)ã€[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)å’Œ[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)çš„æ¯”ç‡æ˜¾è‘—é«˜äºå…¶ä»–[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)ï¼Œå¦‚[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)ã€[äºŒè‹¯å•¶](/è¯ç‰©/äºŒè‹¯å•¶.md)æˆ– [MXE](/è¯ç‰©/MXE.md)ã€‚ç½‘ä¸Šæœ‰å¤§é‡ä½“éªŒæŠ¥å‘Šæè¿°äº†æ»¥ç”¨ 3-MeO-PCP åå‡ºç°çš„â€œç²¾ç¥ç—…æ€§è°µå¦„ã€å¥å¿˜ã€èºç‹‚å’Œå…¶ä»–ä¸¥é‡åæœâ€çš„çŠ¶æ€ã€‚[\[13\]](#cite_note-three-13)[\[14\]](#cite_note-two-14)[\[15\]](#cite_note-one-15) åœ¨æŸäº›æƒ…å†µä¸‹ï¼Œè¿™å¯¼è‡´äº†ä½é™¢æ²»ç–—ï¼Œæœ‰æ—¶ç”šè‡³éœ€è¦ä¸€å‘¨æˆ–æ›´é•¿æ—¶é—´æ‰èƒ½ç¼“è§£ã€‚[\[16\]](#cite_note-six-16)[\[17\]](#cite_note-17)[\[18\]](#cite_note-18)[\[19\]](#cite_note-19)[\[20\]](#cite_note-20)

* ç”¨æˆ·åº”é¿å…è¿ç»­å¤šæ—¥æœç”¨ 3-MeO-PCP æˆ–å¯¹å…¶äº§ç”Ÿä¾èµ–ï¼Œè¿™ä¼¼ä¹æ˜¯è§‚å¯Ÿåˆ°çš„ä¸¥é‡ä¸è‰¯ååº”å‘ç”Ÿçš„ä¸»è¦é£é™©å› ç´ ã€‚
* ä¸åº”è¶…è¿‡å»ºè®®çš„å‰‚é‡èŒƒå›´ï¼Œå› ä¸ºé«˜å‰‚é‡ä¹Ÿä¼šå¼•å‘è¿™äº›å½±å“ã€‚
* ç”¨æˆ·åº”ä»æä½å‰‚é‡å¼€å§‹ï¼Œå¹¶å°½å¯èƒ½ç¼“æ…¢åœ°å¢åŠ å‰‚é‡ã€‚ç”±äºè¯¥è¯ç‰©æ•ˆåŠ›å¼ºï¼Œæœ€å¥½ä½¿ç”¨[æ¶²ä½“å®¹é‡ç»™è¯æ³•](/æ–‡æ¡£/æ¶²ä½“å®¹é‡ç»™è¯æ³•.md)ï¼›å¤§å¤šæ•°æ ‡å‡†æ¯«å…‹ç§¤æ— æ³•å‡†ç¡®ç§°é‡ 10-15mg ä»¥ä¸‹çš„å‰‚é‡ã€‚
* ä¸å»ºè®®åœ¨å®Œå…¨æ¸…é†’ä¹‹å‰[å¼ºè¿«æ€§åŠ é‡](/è¯æ•ˆ/å¼ºè¿«æ€§åŠ é‡.md)ï¼Œè¿™å¯èƒ½å¯¼è‡´å‰‚é‡è¿‡é«˜ã€‚

ç”±äºç²¾ç¥ç—…çš„é£é™©ï¼Œä¸å»ºè®®å°†æ­¤ç‰©è´¨ä¸å…¶ä»–ç‰©è´¨æ··åˆä½¿ç”¨ï¼Œå°¤å…¶æ˜¯[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ã€[è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md)æˆ–å…¶ä»–[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)å¦‚ [MXE](/è¯ç‰©/MXE.md)ã€‚åœ¨æœç”¨å‰ï¼Œåº”å§‹ç»ˆè¿›è¡Œ[ç‹¬ç«‹ç ”ç©¶](https://www.google.com/)ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨æ­¤ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/ä¼¤å®³å‡å°‘æªæ–½.md)ã€‚

### æ³Œå°¿é“æ•ˆåº”

å°±é•¿æœŸã€è¿‡é‡ã€åå¤ä½¿ç”¨å¯¹å¥åº·çš„é•¿æœŸå½±å“è€Œè¨€ï¼Œ3-MeO-PCP ä¼¼ä¹è¡¨ç°å‡ºä¸[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md)å‡ ä¹ç›¸åŒçš„è†€èƒ±å’Œæ³Œå°¿é“é—®é¢˜ï¼Œä½†ç¨‹åº¦è¾ƒè½»ã€‚è¿™å¯èƒ½æ˜¯å› ä¸º 3-MeO-PCP æ¯”æ°¯èƒºé…®æ•ˆåŠ›å¼ºå¾—å¤šï¼Œå› æ­¤éœ€è¦æ¶ˆè€—çš„è¯ç‰©é‡æ˜æ˜¾è¾ƒå°‘ã€‚å³ä½¿ä¸é€šè¿‡æ—¶ä½¿ç”¨ï¼Œå¢åŠ çš„æ³Œå°¿é“æ•ˆåº”ä¹Ÿä¼šä¸å…¶ä»–è¯ç‰©ï¼ˆå¦‚è‹¯ä¸™èƒºï¼‰çš„ä½¿ç”¨å¤åˆã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\] æ°¯èƒºé…®è¯±å‘çš„è†€èƒ±ç‚ç—‡çŠ¶å¯èƒ½å˜å¾—æå…¶ä¸¥é‡ï¼Œå¯æè¿°ä¸ºï¼š

* **å°¿é¢‘** - å°¿é¢‘æ˜¯æŒ‡æ¯éš”å‡ åˆ†é’Ÿå°±éœ€è¦æ’ç©ºè†€èƒ±ã€‚
* **å°¿æ€¥** - è¿™å¯ä»¥æè¿°ä¸ºä¸€ç§çªç„¶çš„ã€å¼ºçƒˆçš„æ’å°¿éœ€æ±‚ã€‚
* **å°¿å‹** - è¿™ä½“éªŒä¸ºè†€èƒ±æŒç»­å……æ»¡çš„æ„Ÿè§‰ï¼Œæ’å°¿åæ— æ³•ç¼“è§£ã€‚
* **ç›†è…”å’Œè†€èƒ±ç–¼ç—›** - ç–¼ç—›å¯èƒ½çªç„¶å‰§çƒˆåœ°å‘å±•ï¼Œç‰¹åˆ«æ˜¯åœ¨è†€èƒ±å……æ»¡å°¿æ¶²æ—¶ã€‚
* **è¡€å°¿** - è¡€å°¿æ˜¯å°¿æ¶²ä¸­å¯è§çš„è¡€æ¶²ã€‚
* **å°¿å¤±ç¦** - è¿™æ˜¯å°¿æ¶²çš„æ¸—æ¼ã€‚

å¯ä»¥é€šè¿‡é¿å…å®šæœŸï¼ˆæ¯å¤©æˆ–æ¯å‘¨ï¼‰ä½¿ç”¨ 3-MeO-PCP å¹¶æ‰‹åŠ¨é™åˆ¶è¯¥ç‰©è´¨çš„ä½¿ç”¨é‡æ¥å‡è½»è¿™äº›å½±å“ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨ {#Dangerous_interactions}

***è­¦å‘Šï¼š*** *è®¸å¤šå•ç‹¬ä½¿ç”¨ç›¸å½“å®‰å…¨çš„ç²¾ç¥æ´»æ€§ç‰©è´¨ï¼Œåœ¨ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com), [DuckDuckGo](https://www.duckduckgo.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚éƒ¨åˆ†åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

* **[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å…´å¥‹å‰‚å’Œè§£ç¦»å‰‚éƒ½æœ‰å¼•å‘[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md)ã€[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)ã€[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—….md)ç­‰ä¸è‰¯å¿ƒç†ååº”çš„é£é™©ï¼Œå½“è¿™ä¸¤ç§ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œè¿™äº›é£é™©ä¼šåŠ å‰§ã€‚
* **[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)** - å› ä¸ºä¸¤è€…éƒ½ä¼šæŠ‘åˆ¶å‘¼å¸ç³»ç»Ÿï¼Œè¿™ç§ç»„åˆå¯èƒ½å¯¼è‡´çªç„¶å¤±å»çŸ¥è§‰ã€å‘•åå’Œå› çª’æ¯è€Œæ­»äº¡çš„é£é™©å¢åŠ ã€‚å¦‚æœå‡ºç°[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md)æˆ–å‘•åï¼Œç”¨æˆ·åº”å°è¯•ä»¥[æ¢å¤ä½“ä½](/æ–‡æ¡£/æ¢å¤ä½“ä½.md)å…¥ç¡ï¼Œæˆ–è®©æœ‹å‹å°†å…¶ç§»è‡³è¯¥ä½“ä½ã€‚
* **[MDMA](/è¯ç‰©/MDMA.md)**ï¼š3-MeO-PCP ä½œä¸ºä¸€ç§æ¸©å’Œçš„è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼Œå¯èƒ½ä¸ MDMA çš„è¡€æ¸…ç´ é‡Šæ”¾äº§ç”Ÿè´Ÿé¢ç›¸äº’ä½œç”¨ã€‚

## æ³•å¾‹åœ°ä½ {#Legal_status}

* **å¥¥åœ°åˆ©ï¼š** æ ¹æ® NPSG (Neue-Psychoaktive-Substanzen-Gesetz Ã–sterreich)ï¼Œ3-MeO-PCP çš„æŒæœ‰ã€ç”Ÿäº§å’Œé”€å”®æ˜¯éæ³•çš„ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
* **å·´è¥¿ï¼š** æˆªè‡³ 2018 å¹´ 5 æœˆ 17 æ—¥ï¼Œ3-MeO-PCP å·²è¢«æ·»åŠ åˆ° Portaria SVS/MS nÂº 344 ä¸­ã€‚æ‹¥æœ‰ã€åˆ†å‘å’Œä½¿ç”¨è¯¥ç‰©è´¨ç°åœ¨è¢«è§†ä¸ºéæ³•ã€‚[\[21\]](#cite_note-21)
* **å¾·å›½ï¼š** 2015 å¹´ 11 æœˆ 21 æ—¥ï¼Œ3-MeO-PCP è¢«æ·»åŠ åˆ°å—æ§ç‰©è´¨æ³•æ¡ˆ ("BtMG") çš„ "Anlage II" ä¸­ï¼Œä½¿å…¶ç”Ÿäº§ã€é”€å”®æˆ–æŒæœ‰å‡å±éæ³•ã€‚[\[22\]](#cite_note-22)
* **ä¸¹éº¦ï¼š** æˆªè‡³ 2015 å¹´ 8 æœˆ 25 æ—¥ï¼Œæ‰€æœ‰ MeO-PCP å¼‚æ„ä½“ï¼ˆåŒ…æ‹¬ 3-MeO-PCPï¼‰å‡è¢«æ·»åŠ åˆ°ä¸¹éº¦çš„éæ³•ç‰©è´¨æ¸…å•ä¸­ã€‚[\[23\]](#cite_note-23)
* **ç‘å…¸ï¼š** ç‘å…¸å…¬å…±å«ç”Ÿå±€äº 2014 å¹´ 11 æœˆ 10 æ—¥å»ºè®®å°† 3-MeO-PCP åˆ—ä¸ºå±é™©ç‰©è´¨ã€‚[\[24\]](#cite_note-24)
* **ç‘å£«ï¼š** 3-MeO-PCP æ˜¯ Verzeichnis E ä¸‹æ˜ç¡®åˆ—å‡ºçš„å—æ§ç‰©è´¨ã€‚[\[25\]](#cite_note-25)
* **åœŸè€³å…¶ï¼š** 3-MeO-PCP è¢«å½’ç±»ä¸ºæ¯’å“ï¼ŒæŒæœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£å‡å±éæ³•ã€‚[\[26\]](#cite_note-Bakanlar_Kurulu_Karar.C4.B1_-_Karar_Say.C4.B1s.C4.B1_:_2013.2F5742-26) [\[27\]](#cite_note-List_of_illegal_substances_for_law-27)
* **è‹±å›½ï¼š** 3-MeO-PCP åœ¨è‹±å›½æ˜¯ B ç±»è¯ç‰©ï¼ŒæŒæœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£å‡å±éæ³•ã€‚ä½œä¸º 1-è‹¯åŸºç¯å·±èƒºçš„è¡ç”Ÿç‰©ï¼Œå…¶ä¸­èƒºè¢« 1-å“Œå•¶åŸºå–ä»£ï¼Œè‹¯ç¯è¿›ä¸€æ­¥è¢«çƒ·æ°§åŸºå–ä»£ï¼Œå®ƒå—åˆ° 2013 å¹´ 2 æœˆ 26 æ—¥ç”Ÿæ•ˆçš„ S.I. 2013/239 æ·»åŠ åˆ°æ»¥ç”¨è¯ç‰©æ³•ä¸­çš„èŠ³åŸºç¯å·±èƒºé€šç”¨æ¡æ¬¾çš„ç®¡åˆ¶ã€‚[\[28\]](#cite_note-28)
* **ç¾å›½ï¼š** 3-MeO-PCP åœ¨ç¾å›½ä¸æ˜¯å—æ§ç‰©è´¨ï¼Œä½†ç”±äºå…¶ä¸ PCP åœ¨ç»“æ„å’Œè¯ç†ä¸Šçš„ç›¸ä¼¼æ€§ï¼Œæ ¹æ®è”é‚¦æ¨¡æ‹Ÿæ³•ï¼Œæ‹¥æœ‰æˆ–åˆ†å‘ç”¨äºäººç±»ä½¿ç”¨çš„ 3-MeO-PCP å¯èƒ½ä¼šè¢«èµ·è¯‰ã€‚
* **æ·å…‹å…±å’Œå›½**ï¼š3-MeO-PCP æ˜¯é™„è¡¨ I å—æ§ç‰©è´¨ã€‚[\[29\]](#cite_note-29)
* **è·å…°**ï¼š3-MeO-PCP æ˜¯é™„è¡¨ I å—æ§ç‰©è´¨ã€‚[\[30\]](#cite_note-30)
* **æ„å¤§åˆ©ï¼š** 3-MeO-PCP æ˜¯é™„è¡¨ I å—æ§ç‰©è´¨ã€‚[\[31\]](#cite_note-31)

## å¦è§ {#See_also}

* [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)
    + [æ¶²ä½“å®¹é‡ç»™è¯æ³•](/æ–‡æ¡£/æ¶²ä½“å®¹é‡ç»™è¯æ³•.md)
* [ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md)
* [è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)
* [èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/èŠ³åŸºç¯å·±èƒºç±»ç‰©è´¨.md)
* [4-MeO-PCP](/è¯ç‰©/4-MeO-PCP.md)
* [PCP](/è¯ç‰©/PCP.md)

## å¤–éƒ¨é“¾æ¥ {#External_links}

* [3-MeO-PCP (Wikipedia)](https://en.wikipedia.org/wiki/3-MeO-PCP)
* [3-MeO-PCP (Erowid Vault)](https://erowid.org/chemicals/3-meo-pcp/)
* [3-MeO-PCP (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=11015)

### è®¨è®ºå’Œåª’ä½“ {#Discussion_and_Media}

* [The Big & Dandy 3-MeO-PCP Thread (Bluelight)](http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2)
* [Interview with a Ketamine Chemist (VICE)](https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2)

## æ–‡çŒ® {#Literature}

* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7â€“8), 614â€“632. <https://doi.org/10.1002/dta.1620>

## å‚è€ƒæ–‡çŒ® {#References}

1. [â†‘](#cite_ref-3MeO3_1-0) The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | <http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2>
2. [â†‘](#cite_ref-3MeO2_2-0) The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | <http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity>
3. [â†‘](#cite_ref-3MeO1_3-0) The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | <http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29>
4. â†‘ [4.0](#cite_ref-psychosis_4-0) [4.1](#cite_ref-psychosis_4-1) [4.2](#cite_ref-psychosis_4-2) 3-MeO-PCP Psychosis (PsychonautWiki) | <https://psychonautwiki.org/wiki/3-MeO-PCP#Toxicity_and_harm_potential>
5. â†‘ [5.0](#cite_ref-Morris2014_5-0) [5.1](#cite_ref-Morris2014_5-1) [5.2](#cite_ref-Morris2014_5-2) Morris, H., Wallach, J. (July 2014). ["From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE"](https://onlinelibrary.wiley.com/doi/10.1002/dta.1620). *Drug Testing and Analysis*. **6** (7â€“8): 614â€“632. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/dta.1620](//doi.org/10.1002%2Fdta.1620). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1942-7603](//www.worldcat.org/issn/1942-7603). 
6. [â†‘](#cite_ref-6) <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984>
7. [â†‘](#cite_ref-.22AMCD.22_7-0) [*Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012*](https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012) 
8. [â†‘](#cite_ref-8) <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984>
9. [â†‘](#cite_ref-chemist_9-0) Morris, H. (2011), [*Interview with a Ketamine Chemist*](https://www.vice.com/en/article/ppzgk9/interview-with-ketamine-chemist-704-v18n2) 
10. [â†‘](#cite_ref-AMCD2_10-0) Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., Iversen, L. (19 March 2013). ["The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor"](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334). *PLOS ONE*. **8** (3): e59334. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1371/journal.pone.0059334](//doi.org/10.1371%2Fjournal.pone.0059334). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1932-6203](//www.worldcat.org/issn/1932-6203). 
11. â†‘ [11.0](#cite_ref-Berar_et._al_11-0) [11.1](#cite_ref-Berar_et._al_11-1) [11.2](#cite_ref-Berar_et._al_11-2) Berar, A., Allain, J.-S., Allard, S., Lefevre, C., Baert, A., Morel, I., Bouvet, R., Gicquel, T. (December 2019). ["Intoxication with 3-MeO-PCP alone: A case report and literature review"](https://journals.lww.com/10.1097/MD.0000000000018295). *Medicine*. **98** (52): e18295. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1097/MD.0000000000018295](//doi.org/10.1097%2FMD.0000000000018295). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0025-7974](//www.worldcat.org/issn/0025-7974). 
12. [â†‘](#cite_ref-12) Bakota, E., Arndt, C., Romoser, A. A., Wilson, S. K. (September 2016). ["Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method"](https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkw056). *Journal of Analytical Toxicology*. **40** (7): 504-510. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/jat/bkw056](//doi.org/10.1093%2Fjat%2Fbkw056). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0146-4760](//www.worldcat.org/issn/0146-4760). 
13. [â†‘](#cite_ref-three_13-0) The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | <http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2>
14. [â†‘](#cite_ref-two_14-0) The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | <http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity>
15. [â†‘](#cite_ref-one_15-0) The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | <http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29>
16. [â†‘](#cite_ref-six_16-0) BÃ¤ckberg, M., Beck, O., Helander, A. (November 2015). "Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project". *Clinical Toxicology (Philadelphia, Pa.)*. **53** (9): 856-864. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.3109/15563650.2015.1079325](//doi.org/10.3109%2F15563650.2015.1079325). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-9519](//www.worldcat.org/issn/1556-9519). 
17. [â†‘](#cite_ref-17) The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10 | Post #448 by Sekio (Administrator) | <http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821>
18. [â†‘](#cite_ref-18) The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | <http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322>
19. [â†‘](#cite_ref-19) The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 | 23-06-2015 11:53 | Post #5 by Confield | <http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675>
20. [â†‘](#cite_ref-20) [*3-MeO-PCP - Erowid Exp - â€œSo Strong Iâ€™m Shockedâ€*](https://www.erowid.org/experiences/exp.php?ID=103972) 
21. [â†‘](#cite_ref-21) List of controlled substances: Portaria SVS/MS nÂº 344 (Portuguese) | <http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial>
22. [â†‘](#cite_ref-22) [*30. BtMÃ„ndVO in Kraft getreten: 6 neue Stoffe wurden ins BtMG aufgenommen*](https://community.beck.de/2015/11/23/30-btm-ndvo-in-kraft-getreten-6-neue-stoffe-wurden-ins-btmg-aufgenommen-0), 2015 
23. [â†‘](#cite_ref-23) [*BekendtgÃ¸relse om euforiserende stoffer - ni nye stoffer tilfÃ¸jet*](https://laegemiddelstyrelsen.dk/da/nyheder/2015/bekendtgoerelse-om-euforiserende-stoffer-ni-nye-stoffer-tilfoejet/) 
24. [â†‘](#cite_ref-24) Cannabinoider fÃ¶reslÃ¥s bli klassade som hÃ¤lsofarlig vara | <http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/>
25. [â†‘](#cite_ref-25) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
26. [â†‘](#cite_ref-Bakanlar_Kurulu_Karar.C4.B1_-_Karar_Say.C4.B1s.C4.B1_:_2013.2F5742_26-0) [*BaÅŸbakanlÄ±k MevzuatÄ± GeliÅŸtirme ve YayÄ±n Genel MÃ¼dÃ¼rlÃ¼ÄŸÃ¼*](https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm) 
27. [â†‘](#cite_ref-List_of_illegal_substances_for_law_27-0)  <https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf>
28. [â†‘](#cite_ref-28) [*The Misuse of Drugs Act 1971 (Amendment) Order 2013*](https://www.legislation.gov.uk/uksi/2013/239/introduction/made) 
29. [â†‘](#cite_ref-29) info@aion.cz, A. C.-, [*463/2013 Sb. NaÅ™Ã­zenÃ­ vlÃ¡dy o seznamech nÃ¡vykovÃ½ch lÃ¡tek*](https://www.zakonyprolidi.cz/cs/2013-463) 
30. [â†‘](#cite_ref-30) [*Opiumwet, Lijst I, (Dutch)*](https://wetten.overheid.nl/BWBR0001941/2023-09-12#BijlageI), 2023 
31. [â†‘](#cite_ref-31) <https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.dataPubblicazioneGazzetta=2021-10-18&atto.codiceRedazionale=21A06118&tipoSerie=serie_generale&tipoVigenza=originario>